Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

Agilent MMR IHC panel approved as a CDx for colorectal cancer

October 2025—Agilent Technologies MMR IHC Panel pharmDx (Dako Omnis) has received FDA approval as a companion diagnostic test for colorectal cancer. The test aids in identifying mismatch repair deficient colorectal cancer patients who are eligible for treatment with Bristol Myers Squibb’s Opdivo (nivolumab) or Opdivo in combination with Yervoy (ipilimumab). It was developed and validated to detect the loss of function of any of the four MMR proteins in formalin-fixed, paraffin-embedded colorectal cancer tissue.

Magnified Learning offers consulting, educational services

October 2025—Magnified Learning offers consulting services across the spectrum of health care operations, including supply chain management, revenue cycle optimization, operational excellence, and organizational change management. The company’s approach leverages next-generation Lean Six Sigma, clinical integration strategies, and advanced technology platforms to create a sustainable alignment between operational performance and financial outcomes. Magnified Learning also offers online certification programs that feature sophisticated online learning management systems with self-paced curricula, comprehensive content previews, and embedded assessment tools compatible across all major operating systems. Each certification includes continuous learning pathways and recertification opportunities.

Roche mass spec test categorized as moderate complexity

October 2025—The Food and Drug Administration has categorized Roche’s Ionify 25-Hydroxy Vitamin D total assay as moderate complexity under the Clinical Laboratory Improvement Amendments of 1988. Roche reported that this is the first time a mass-spectrometry-based test has achieved this designation.

Eppendorf introduces next-generation mechanical pipettes

October 2025—Eppendorf has launched the Eppendorf Research 3 Neo mechanical pipette. Users can choose between two volume settings and speeds. The pipette can be adjusted for different liquid types, tip geometries, and reverse pipetting and a volume lock feature prevents unintentional volume changes. The use of ColorTag marking rings provides color-coded identification.

Haystack MRD ctDNA test gets breakthrough device designation

October 2025—The Food and Drug Administration has granted breakthrough device designation for Quest Diagnostic’s Haystack MRD circulating tumor DNA test. The test is used for identifying minimal residual disease in patients with stage two colorectal cancer following curative-intent surgical treatment who may benefit from adjuvant therapy in accordance with therapeutic product labeling.

FDA clears assay to detect CTX-M enzymes

October 2025—The FDA has cleared Hardy Diagnostics’ NG-Test CTX-M Multi, an in vitro diagnostic immunoassay for the qualitative detection of CTX-M enzymes (groups 1, 2, 8, 9, and 25) from pure colonies of Enterobacterales suspected of extended-spectrum beta-lactamase production. These enzymes confer resistance to many beta-lactam antibiotics, making infections more difficult to treat. The test delivers results in 15 minutes.

Quest introduces testing for Oropouche virus

September 2025—Quest Diagnostics has launched a diagnostic laboratory test for the Oropouche virus, an emerging virus in the Americas that is spread to people by infected biting midges and some species of mosquitoes. The viral disease presents clinically with symptoms that overlap with those of other arboviral diseases such as Dengue, Zika, and chikungunya. Quest’s laboratory in San Juan Capistrano, Calif., will perform the test using PCR technology, with serology testing to follow later this quarter.

C2N launches RUO blood tests for Alzheimer’s disease

September 2025—C2N Diagnostics has launched two plasma assays for research use only. C2N eMTBR-tau243 (endogenous microtubule binding region) is a blood test that selectively detects a specific region of tau; this fragment has been shown to closely track insoluble tau aggregates within neurofibrillary tangles in Alzheimer’s disease. The assay builds on the existing C2N eMTBR-tau243 test in cerebrospinal fluid launched by the company nearly two years ago. C2N obtained exclusive rights for these technologies from the Bateman Lab at WashU Medicine, St. Louis, Mo. The company plans to integrate the new plasma C2N eMTBR-tau243 assay into clinical routine in the future.

Bruker MALDI Biotyper systems awarded ACT label

September 2025—Bruker’s MALDI Biotyper Sirius and Sirius One systems have been awarded the My Green Lab ACT Ecolabel. The MALDI Biotyper systems for microbial identification received an Environmental Impact Factor score of 26.8 (EU and U.K.) and 35.4 (United States).

Agilent expands Dako Omnis family

September 2025—Agilent Technologies is introducing three models to its Dako Omnis family of instruments—the Omnis 110, 165, and 165 Duo—designed to provide laboratories with the flexibility to tailor staining solutions according to volume, workflow, and diagnostic requirements. The Dako Omnis 110 is for low- to medium-volume labs and delivers up to 110 immunohistochemistry slides per day. The Dako Omnis 165 is engineered for medium-high volume labs and has a throughput of up to 165 IHC slides per day, and the 165 Duo has the capacity to run IHC and in situ hybridization slides. All models feature continuous, case-based processing and shared reagents. A newly integrated direct connection for deionized water and nonhazardous waste reduces handling time.

MARKETPLACE

TRENDING